Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment
Status:
Completed
Trial end date:
2017-01-28
Target enrollment:
Participant gender:
Summary
Background: Pasireotide treatment is strictly associated with glucose metabolism impairment.
The aim of the study was to evaluate the effect of pasireotide on β -cell and adipose
function in patients with Cushing's disease (CD).
Methods: Clinical and hormonal parameters, insulin secretion, evaluated by homostasis model
assessment (HOMA-β) and by the area under the curve (AUC2h) of C-peptide during a mixed meal
tolerance test and insulin sensitivity, evaluated by the euglycemic hyperinsulinemic clamp,
were evaluated in 12 patients with active CD before and after 12 months of pasireotide.
Circulating adipokines were evaluated in patients with CD compared to a matched group of 12
diabetic patients.